Equities analysts expect Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings per share of $2.19 for the current fiscal quarter, Zacks Investment Research reports. Eleven analysts have issued estimates for Zimmer Biomet’s earnings. The highest EPS estimate is $2.21 and the lowest is $2.17. Zimmer Biomet posted earnings of $2.10 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 4.3%. The business is scheduled to report its next quarterly earnings report on Tuesday, January 29th.
On average, analysts expect that Zimmer Biomet will report full-year earnings of $7.64 per share for the current financial year, with EPS estimates ranging from $7.60 to $7.70. For the next year, analysts anticipate that the business will report earnings of $7.90 per share, with EPS estimates ranging from $7.80 to $8.40. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Zimmer Biomet.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.03. The business had revenue of $1.84 billion for the quarter, compared to analyst estimates of $1.84 billion. Zimmer Biomet had a return on equity of 12.88% and a net margin of 22.42%. The company’s revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.72 EPS.
A number of brokerages have recently commented on ZBH. Needham & Company LLC lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating and set a $150.00 price objective on the stock. in a report on Monday, August 13th. BTIG Research began coverage on Zimmer Biomet in a research report on Thursday, August 16th. They set a “neutral” rating on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $150.00 price target on shares of Zimmer Biomet in a research report on Monday, August 27th. Oppenheimer reissued a “buy” rating on shares of Zimmer Biomet in a research report on Monday, August 27th. Finally, Morgan Stanley boosted their price target on Zimmer Biomet from $140.00 to $149.00 and gave the stock an “overweight” rating in a research report on Thursday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $134.90.
Shares of NYSE ZBH traded up $2.06 during midday trading on Friday, hitting $117.02. The stock had a trading volume of 1,256,070 shares, compared to its average volume of 978,407. The firm has a market capitalization of $23.87 billion, a P/E ratio of 14.57, a P/E/G ratio of 2.37 and a beta of 1.16. Zimmer Biomet has a 1-year low of $104.28 and a 1-year high of $134.55. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.89 and a quick ratio of 0.96.
In other news, VP Chad F. Phipps sold 30,100 shares of the company’s stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $132.37, for a total value of $3,984,337.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.71% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of ZBH. Whitener Capital Management Inc. purchased a new stake in shares of Zimmer Biomet during the third quarter valued at $109,000. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Zimmer Biomet by 5,200.0% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,007 shares of the medical equipment provider’s stock worth $112,000 after acquiring an additional 988 shares during the period. Girard Partners LTD. acquired a new stake in Zimmer Biomet during the 3rd quarter worth about $114,000. Twin Tree Management LP grew its holdings in Zimmer Biomet by 198.0% during the 3rd quarter. Twin Tree Management LP now owns 1,208 shares of the medical equipment provider’s stock worth $159,000 after acquiring an additional 2,441 shares during the period. Finally, Ancora Advisors LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $188,000. Institutional investors and hedge funds own 87.10% of the company’s stock.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Article: NASDAQ Stock Market Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.